Deferoxamine, Cerebrovascular Hemodynamics, and Vascular Aging
Authors:
- Farzaneh A. SorondFSFarzaneh A. Sorond
- Can Ozan TanCTCan Ozan Tan
- Sarah LaRoseSLSarah LaRose
- Andrew D. MonkAMAndrew D. Monk
- Raina FichorovaRFRaina Fichorova
- Stanthia RyanSRStanthia Ryan
- Lewis A. LipsitzLLLewis A. Lipsitz
- 1 September 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 46 (9) , 2576-2583
Abstract
Background and Purpose—: Iron chelation therapy is emerging as a novel neuroprotective strategy. The mechanisms of neuroprotection are diverse and include both neuronal and vascular pathways. We sought to examine the effect of iron chelation on cerebrovascular function in healthy aging and to explore whether hypoxia-inducible transcription factor-1 activation may be temporally correlated with vascular changes. Methods—: We assessed cerebrovascular function (autoregulation, vasoreactivity, and neurovascular coupling) and serum concentrations of vascular endothelial growth factor and erythropoietin, as representative measures of hypoxia-inducible transcription factor-1 activation, during 6 hours of deferoxamine infusion in 24 young and 24 older healthy volunteers in a randomized, blinded, placebo-controlled cross-over study design. Cerebrovascular function was assessed using the transcranial Doppler ultrasound. Vascular endothelial growth factor and erythropoietin serum protein assays were conducted using the Meso Scale Discovery platform. Results—: Deferoxamine elicited a strong age- and time-dependent increase in the plasma concentrations of erythropoietin and vascular endothelial growth factor, which persisted ≤3 hours post infusion (age effect P =0.04; treatment×time P P P P =0.04). Conclusions—: Deferoxamine infusion improved cerebrovascular function, particularly in older individuals. The temporal association between improved cerebrovascular function and increased serum vascular endothelial growth factor and erythropoietin concentrations is supportive of shared hypoxia-inducible transcription factor-1–regulated pathways. Therefore, pharmacological activation of hypoxia-inducible transcription factor-1 to enhance cerebrovascular function may be a promising neuroprotective strategy in acute and chronic ischemic syndromes, especially in elderly patients. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT013655104.Keywords
This publication has 52 references indexed in Scilit:
- High-Dose Atorvastatin Enhances Impaired Cerebral Vasomotor ReactivityJournal of Stroke and Cerebrovascular Diseases, 2012
- Effect of Combination Therapy with the Angiotensin Receptor Blocker Losartan plus Hydrochlorothiazide on Brain Perfusion in Patients with both Hypertension and Cerebral Hemodynamic Impairment due to Symptomatic Chronic Major Cerebral Artery Steno-Occlusive Disease: A SPECT StudyCerebrovascular Diseases, 2012
- Hypoxia-Inducible Factors in Physiology and MedicineCell, 2012
- Impaired hypoxic response in senescent mouse brainInternational Journal of Developmental Neuroscience, 2011
- Neurovascular coupling is impaired in slow walkers: The MOBILIZE Boston StudyAnnals of Neurology, 2011
- Cerebrovascular hemodynamics, gait, and falls in an elderly populationNeurology, 2010
- Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodellingCardiovascular Research, 2010
- Sympathetic Control of the Cerebral Vasculature in HumansStroke, 2010
- Real-Time Imaging of HIF-1α Stabilization and DegradationPLOS ONE, 2009
- Desferrioxamine Induces Delayed Tolerance against Cerebral Ischemia in Vivo and in VitroJournal of Cerebral Blood Flow & Metabolism, 2002